The aim of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of NewDrug3601, a synthetic parathyroid hormone analogue. It is being conducted in healthy volunteers and patients with hypoparathyroidism (HP).
MissionTEC has been mandated to carry out the necessary tasks for the follow-up of the study in the patients’ homes.